Short Interest in Enliven Therapeutics, Inc. (NASDAQ:ELVN) Decreases By 6.5%

Enliven Therapeutics, Inc. (NASDAQ:ELVNGet Free Report) was the recipient of a large decline in short interest in January. As of January 15th, there was short interest totalling 5,150,000 shares, a decline of 6.5% from the December 31st total of 5,510,000 shares. Approximately 26.9% of the company’s stock are short sold. Based on an average trading volume of 131,200 shares, the days-to-cover ratio is currently 39.3 days.

Enliven Therapeutics Trading Down 1.6 %

Shares of Enliven Therapeutics stock opened at $16.28 on Wednesday. Enliven Therapeutics has a 12-month low of $9.80 and a 12-month high of $25.34. The firm has a market capitalization of $667.48 million, a price-to-earnings ratio of 5.09 and a beta of 1.06. The firm’s 50 day simple moving average is $12.97 and its two-hundred day simple moving average is $14.21.

Enliven Therapeutics (NASDAQ:ELVNGet Free Report) last issued its quarterly earnings results on Thursday, November 9th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.02). On average, sell-side analysts predict that Enliven Therapeutics will post -2.24 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Joseph P. Lyssikatos sold 8,546 shares of the business’s stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $13.08, for a total transaction of $111,781.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Samuel Kintz sold 8,026 shares of the business’s stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $13.08, for a total transaction of $104,980.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Joseph P. Lyssikatos sold 8,546 shares of the company’s stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $13.08, for a total transaction of $111,781.68. The disclosure for this sale can be found here. Insiders sold a total of 84,481 shares of company stock worth $1,207,801 in the last 90 days. 45.80% of the stock is owned by corporate insiders.

Institutional Trading of Enliven Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. boosted its holdings in Enliven Therapeutics by 4,476.0% during the second quarter. BlackRock Inc. now owns 1,546,475 shares of the company’s stock worth $31,564,000 after buying an additional 1,512,680 shares in the last quarter. Commodore Capital LP boosted its holdings in Enliven Therapeutics by 35.6% during the second quarter. Commodore Capital LP now owns 2,348,272 shares of the company’s stock worth $47,928,000 after buying an additional 616,907 shares in the last quarter. State Street Corp boosted its holdings in Enliven Therapeutics by 4,847.5% during the second quarter. State Street Corp now owns 466,251 shares of the company’s stock worth $9,516,000 after buying an additional 456,827 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Enliven Therapeutics by 1,071.1% during the second quarter. Geode Capital Management LLC now owns 414,444 shares of the company’s stock valued at $8,459,000 after purchasing an additional 379,056 shares in the last quarter. Finally, Northern Trust Corp purchased a new position in Enliven Therapeutics during the second quarter valued at $3,999,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

(Get Free Report)

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

See Also

Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.